Bruce Power and its partners are celebrating the third anniversary of their partnership to produce medical isotopes.
The company, along with its partners Isogen and ITM Isotope Technologies Munich, as well as Saugeen Ojibway Nation (SON) has provided the world’s health care community with a stable source of the isotope Lutetium-177.
Lutetium-177 is a cancer fighting medical isotope that is used to treat prostate cancers and neuroendocrine tumours.
As part of its Canadian at Our Core campaign, Bruce Power is committed to growing Canada’s leadership role as a producer medical isotopes, taking steps to help the Canadian Nuclear Isotope Council (CNIC) and Canadian Medical Isotope Ecosystem (CMIE) in the goal to double the country’s isotope production by 2030.
Part of the funding for the new isotope production system comes from Innovation, Science and Economic Development Canada’s Strategic Innovation Fund (SIF), which supports SON in expanding its partnership with Bruce Power. SON’s investment, enhanced by SIF, advances critical infrastructure and also provides stable isotope revenue streams to SON, enabling greater participation and capacity-building.
Bruce Power has successfully shipped isotopes generated from its station to ITM’s manufacturing facility in Germany for processing pharmaceutical-grade, non-carrier-added lutetium-177.
ITM is a leading supplier of the isotope to health-care facilities around the world for use in various clinical and commercial radiopharmaceutical cancer treatments.